CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Inclusion Criteria: Inclusion criteria only for AML:

1. Histologically confirmed diagnosis of CD70 AML per the US National ComprehensiveCancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia (2016.v1);
2. Relapsed or refractory CD70+ AML (meeting one of the following conditions):
3. CR not achieved after standardized chemotherapy;
4. CR achieved following the first induction, but CR duration is less than 12months;
5. Ineffectively after first or multiple remedial treatments;
6. 2 or more relapses;
7. The number of primordial cells in bone marrow is > 5% (by morphology), and/or > 0.01% (by flowcytometry);
8. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine ≤ 176.8 umol/L;
9. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
10. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
11. Estimated survival time ≥ 3 months;
12. ECOG performance status 0 to 2;
13. Patients or their legal guardians volunteer to participate in the studyand sign theinformed consent. Inclusion criteria only for NHL:
14. No gender and age limit;
15. Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from CLL/SLL,PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma (2016);
16. Relapsed or refractory CD70+ NHL (meeting one of the following conditions):
17. No response or relapse after second-line or above chemotherapy regimens;
18. Primary drug resistance;
19. Relapse after auto-HSCT;
20. At least one assessable tumor lesion per Lugano 2014 criteria Inclusion criteria only for MM:
21. Histologically confirmed diagnosis of CD70 multiple myeloma (MM)：
22. According to the diagnostic criteria of IMWG multiple myeloma, the diagnosis wasrecurrent / refractory multiple myeloma
23. Cases with recurrent positive minimal residual disease;
24. Extramedullary leision which is hard to be eradicated by chemotherapy orradiotherapy.
25. No gender and age limit;
26. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal,creatinine ≤ 176.8 umol/L;
27. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;
28. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;
29. Estimated survival time ≥ 3 months;
30. ECOG performance status 0 to 2;
31. Patients or their legal guardians volunteer to participate in the studyand sign theinformed consent. Common inclusion criteria :
32. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit of normal,creatinine ≤ 176.8 umol/L;
33. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
34. No active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%;
35. Estimated survival time ≥ 3 months;
36. ECOG performance status 0 to 2;
37. Patients or their legal guardians volunteer to participate in the study and sign theinformed consent -

Exclusion Criteria:

1. History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascularischemia, and cerebrovascular hemorrhagic diseases;
2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severearrhythmia in the past;
3. Pregnant (or lactating) women;
4. Patients with severe active infections (excluding simple urinary tract infection andbacterial pharyngitis);
5. Active infection of hepatitis B virus or hepatitis C virus;
6. Concurrent therapy with systemic steroids within 2 weeks prior to screening, exceptfor the patients recently or currently receiving inhaled steroids;
7. Previously treated with any CAR-T cell product or other geneticallymodified T celltherapies;
8. Creatinine >2.5mg/dl, or ALT / AST>3 times of normal amounts, or bilirubin>2.0 mg/dl;
9. Other uncontrolled diseases that were not suitable for this trial;
10. Patients with HIV infection;
11. Any situations that the investigator believes may increase the risk of patients orinterfere with the results of study. -